Medscape2m
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Medscape9m
Two Lung Cancer Drugs Recommended by EMA
Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.
Merck receives CHMP opinion recommending approval of Keytruda
Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...
Le Lézard24m
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary ...
Trump’s RFK Pick Weighs on Vaccine Makers
Kennedy, a vaccine skeptic, has promised sweeping changes to food and drug regulation and government-funded scientific ...
Ipsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ
Revenue decreased by 3.22%, or $0.41 million, to $12.41 million, down from $12.82 million in Q3 2023. For the nine months ended September 30, 2024, revenue rose by 7.1%, or $2.67 million, reaching $40 ...